TSX:ONC 0.93 CAD +0.08 +9.41% Volume: 683,966 April 17, 2015
NASDAQ:ONCY 0.76 USD +0.07 +10.27% Volume: 4,203,929 April 17, 2015

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

April 17, 2015 Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Malignant Gliomas
April 15, 2015 Oncolytics Biotech® Inc. Presents at UK Immuno-oncology Meeting
April 13, 2015 Media Advisory - Oncolytics Biotech® Inc. to Participate in the 14th Annual Needham Healthcare Conference
Sign up to receive e-mail updates *